APIS Assay Technologies is leveraging the transformational power of systems biology and big data to directly address the historical failures of translating biomarkers into clinical utility.
By linking genomic biomarker research and clinical history datasets APIS is building unique and comprehensive knowledge bases. Novel biomarkers are identified through the application of ML‑oriented data analysis approaches and AI-enabled data comprehension. In addition this approach enables the assessment of putative candidate biomarkers from commercial and academic partners.
Operating under an ISO 13485 QMS APIS has the demonstrable expertise to then develop and manufacture such innovative and disease-agnostic biomarkers as molecular IVD products for delivery into regulated global markets.
Through working with a variety of both open (‘Wet’) and closed (‘Dry’) diagnostic platforms including POCT and near-patient devices, APIS seeks to maximise the benefit to patients and stakeholders alike for MDx, CDx and CoDx tests.